|Karolinska Development AB -- Sweden Stock|| |
SEK 10 1.7 20.48%
Dr. Jim Van Heusden, Ph.D. has served as Chief Executive Officer of Karolinska Development AB since March 3, 2015. Jim Van Heusden has over 20 years of experience within VC, research and development within the pharmaceutical industry, including as Founder and Managing Director at bioskills and as Partner at the European investment company Gimv . During his appointment at Gimv he also served as a Board member in several biotech companies including Multiplicom NV, Ablynx NV, ActoGeniX NV, Pronota NV and Prosensa. During 19932001, Jim Van Heusden worked as Senior Scientist at Janssen Pharmaceuticals . He has a Ph.D. in molecular and cellular biology from the University of Maastricht.
Age: 44 CEO Since 2015 Ph.D
46 8 52 48 60 70 http://www.karolinskadevelopment.com
The company has return on total asset (ROA)
of (4.21) %
which means that it has lost $4.21 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (156.17) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 357.55 M in total debt with debt to equity ratio (D/E) of 868.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Karolinska Development AB has Current Ratio of 24.99 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Karolinska Development AB is a VC firm specializing in investments in growth capital, seed stage, and early stage companies. Karolinska Development AB (KDEV) is traded on Stockholm Stock Exchange in Sweden. It is located in Solna, and employs 13 people.